← Leaderboards
Ann J Brown
Duke University
$765,225
Attributed
$765,225
Total exposure
3
Grants
1
Lead (contact PI)
Attributed= this PI's even-split share of every grant they're on (the fair, additive number). Exposure = full size of all those grants. They are the sole PI on all grants (the two match).
Funding over time
peak $182.7K · FY2005–06$200K$150K$100K$50K$0
'05
'06
Funding mix
By agency
NIH$765,225 · 3
By mechanism
K23$693,247 · 1
M01$71,978 · 2
Top collaborators
No co-investigators on record.
Most similar at Duke University
Same institution · by research overlap
- Mark N Feinglos$8,642,419
- Rima F Kaddurah-Daouk$56,438,861
- William E Kraus$34,726,553
- Farshid Guilak$32,330,672
- Laura P Svetkey$25,471,440
Others in their field
Top investigators on “Clinical Research”
- David Heimbrook · Leidos Biomedical Research, Inc.$1,040,569,537
- Leonard Freedman · Leidos Biomedical Research, Inc.$975,089,882
- Lawrence Corey · Fred Hutchinson Cancer Center$739,766,552
- Sonia M Thomas · Research Triangle Institute$700,865,642
- Jeffrey P Krischer · University Of South Florida$611,867,176
- Barton F Haynes · Duke University$538,862,577
Research focus
Clinical ResearchHuman SubjectHuman Therapy EvaluationInsulin Sensitivity /ResistancePolycystic Ovary SyndromeDisease /Disorder Prevention /ControlPatient Oriented ResearchExerciseFemaleBehavioral /Social Science Research TagAndrogensBody ImageLifestyleQuality Of LifeInhibitor /AntagonistGlucagonDiabetes Mellitus TherapyNoninsulin Dependent Diabetes MellitusDrug Screening /EvaluationHormone ReceptorGlucose Tolerance TestPhysical Therapy
Grant awards (9)
Insulin Resistance and Polycystic Ovary Syndrome$117,368
K23 · FY2006 · HL · contact PI
Insulin Resistance and Polycystic Ovary Syndrome$151,335
K23 · FY2005 · HL
INSULIN RESISTANCE, EXERCISE AND POLYCYSTIC OVARY SYNDROME$31,382
M01 · FY2005 · RR
Insulin Resistance and Polycystic Ovary Syndrome$152,179
K23 · FY2004 · HL
Insulin Resistance, Exercise and Polycystic Ovary Syn.$40,596
M01 · FY2004 · RR
Insulin Resistance and Polycystic Ovary Syndrome$150,915
K23 · FY2003 · HL
Insulin Resistance and Polycystic Ovary Syndrome$121,450
K23 · FY2002 · HL
Efficacy &safety of glucagon receptor antagonist BAY 27-9955 in NIDDM$0
M01 · FY2000 · RR
Efficacy &safety of glucagon receptor antagonist BAY 27-9955 in NIDDM$0
M01 · FY2000 · RR